Recently Karo Bio acquired 100 percent of the drug research company Tanomed AB for 20 MSEK. This deal gives Karo Bio access to Tanomed’s nasal spray to relieve and prevent the progression of the common cold by reinforcing the body’s own defenses, according to Biotech Umeå.
The patented technology is based on Swedish research in cooperation with Umeå University and with business development support from Umeå Biotech Incubator, Biotech Umeå says. The nasal spray relies on a combination of the enzyme glucose oxidase with glucose, which results in a rise in hydrogen peroxide in the nose. The elevated levels of hydrogen peroxide counteract rhinovirus infections, as well as other viral and bacterial pathogens. Several clinical studies have shown that early treatment can prevent or reduce worsening symptoms.
“This product has great international potential. We expect a market launch to take place within one to one-and-a-half years,” says Anders Lönner, executive chairman of Karo Bio.
Source: Biotech Umeå
